[go: up one dir, main page]

WO2003018609A3 - Application of peptide conjugates to alzheimer's disease - Google Patents

Application of peptide conjugates to alzheimer's disease Download PDF

Info

Publication number
WO2003018609A3
WO2003018609A3 PCT/US2002/026889 US0226889W WO03018609A3 WO 2003018609 A3 WO2003018609 A3 WO 2003018609A3 US 0226889 W US0226889 W US 0226889W WO 03018609 A3 WO03018609 A3 WO 03018609A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
application
peptide conjugates
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/026889
Other languages
French (fr)
Other versions
WO2003018609A2 (en
Inventor
Stanley Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002327514A priority Critical patent/AU2002327514A1/en
Publication of WO2003018609A2 publication Critical patent/WO2003018609A2/en
Publication of WO2003018609A3 publication Critical patent/WO2003018609A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A chemical compound and a method for its use in the diagnosis and treatment of Alzheimer's disease in which the at least the sequence of the D-isomers of the amino acids (phenylalanine-phenylalanine-valine-leucine-lysine) is capable of crossing the blood brain barrier, recognizing the formation of plaques characteristic of the pathogenesis of Alzheimer's disease, and intefering with the formation of fibril from beta amyloid peptide effecting an inhibition of the disease process.
PCT/US2002/026889 2001-08-23 2002-08-23 Application of peptide conjugates to alzheimer's disease Ceased WO2003018609A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002327514A AU2002327514A1 (en) 2001-08-23 2002-08-23 Application of peptide conjugates to alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31438201P 2001-08-23 2001-08-23
US60/314,382 2001-08-23

Publications (2)

Publication Number Publication Date
WO2003018609A2 WO2003018609A2 (en) 2003-03-06
WO2003018609A3 true WO2003018609A3 (en) 2003-10-16

Family

ID=23219731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026889 Ceased WO2003018609A2 (en) 2001-08-23 2002-08-23 Application of peptide conjugates to alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2002327514A1 (en)
WO (1) WO2003018609A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608960D0 (en) * 2006-05-05 2006-06-14 St Georges Hosp Medical School Imaging agent
WO2008050133A2 (en) * 2006-10-27 2008-05-02 Zapaloid Limited Inhibition of beta-amyloid aggregation
GB0716885D0 (en) * 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
EP2766094B1 (en) * 2011-10-10 2019-03-06 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
CN113061161B (en) * 2021-04-02 2023-09-12 河南省农业科学院动物免疫学重点实验室 Inhibitory peptide ligand of targeting amyoid-beta structure and application
CN114933635B (en) * 2021-08-29 2023-05-19 武汉夫图生物科技有限公司 Nano small peptide FH and application thereof in preparation of drugs for treating and preventing fundus vascular diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Also Published As

Publication number Publication date
WO2003018609A2 (en) 2003-03-06
AU2002327514A1 (en) 2003-03-10

Similar Documents

Publication Publication Date Title
WO2002094191A3 (en) Detection of alzheimer's amyloid by magnetic resonance imaging
EP2082747A3 (en) Treatment for Alzeimer's disease
FR2824568B1 (en) PROCESS FOR THE PREPARATION OF HUMAN IMMUNOGLOBULIN CONCENTRATES FOR THERAPEUTIC USE
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
WO2003039454A3 (en) Beta-secretase inhibitors and methods of use
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU2002363825A1 (en) Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
WO2000076489A3 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003018609A3 (en) Application of peptide conjugates to alzheimer's disease
WO2002035987A3 (en) METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
WO2003068147A3 (en) Treatments for neurotoxicity in alzheimer’s disease
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
HUP0301205A3 (en) Use of pamoic acid, its derivatives and its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates and process for preparation of the compounds
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
EE200000478A (en) Peptide, gene encoding it, diagnostic reagent and diagnostic kit, for use in the treatment of rickettsia
AU2002303957A1 (en) Method of treating alzheimer's disease with se-containing peptide
FR2800066B1 (en) PROCESS FOR THE PREPARATION OF KETONES BY PYROGENATION OF ALDEHYDES, ALCOHOLS, ACIDS OR ESTERS
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
WO2001093896A3 (en) A method of treatment of alzheimer's disease with a protein extractable from mammalian organs
WO2004074313A3 (en) Methods for prediction of amyloid fibril formation and identification of peptides useful as therapeutic and diagnostic agents
RU2001108801A (en) METHOD FOR PREVENTION AND TREATMENT OF GALLSTONE DISEASE
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease
WO2002000828A3 (en) A novel polypeptide, a zinc-finger protein 34 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP